Blog

Jun 2019

A Big Thank You to All Our Poster Visitors at DIA 2019!

By |2019-07-01T17:01:11+02:00June 27, 2019|Blog|Comments Off on A Big Thank You to All Our Poster Visitors at DIA 2019!

¡Buenos DIAs! Blown away that so many folks visited our QTLs vs KRIs poster presentation! Here is the infographic in the event that you plan to do home-work.

May 2019

Centralized Monitoring: a Greater Advantage to a Broader Range of Trials

By |2024-03-08T10:24:37+02:00May 2, 2019|Blog, Free Infographics|Comments Off on Centralized Monitoring: a Greater Advantage to a Broader Range of Trials

Regulatory bodies are unanimous, today's clinical research needs Centralized Monitoring. We summarized Centralized Monitoring the infographic way, download your free copy here...

Apr 2019

FDA Q&A Draft Guidance Document: The RBM Process-Technology Fit

By |2019-05-27T15:16:11+02:00April 15, 2019|Blog|Comments Off on FDA Q&A Draft Guidance Document: The RBM Process-Technology Fit

Our expert team reviewed the March 2019 RBM Q&A draft guidance document and extended the FDA guidance with RBM solution specific insights and a MindMap to help you even further.

Apr 2019

RBQM Software Features: What’s a Risk Flower chart?

By |2019-08-07T19:11:02+02:00April 9, 2019|Blog, Neat Features|1 Comment

Neat Features: wanting to dig a little deeper into the neat software features that make your risk-management life easy? Well, you’ve come to the right place. Learn more about Risk Flowers charts - a bunch of information.

Feb 2019

3 Critical Aspects of Clinical Trial Conduct that Affect the Totality of Evidence

By |2019-02-27T20:13:40+02:00February 27, 2019|Blog|Comments Off on 3 Critical Aspects of Clinical Trial Conduct that Affect the Totality of Evidence

Even without it being mandated, health authorities typically expect pharma and biotech companies to conduct two well-controlled Phase 3 trials demonstrating efficacy and safety. Still today this principle ensues discussions regarding the quantity and quality of the evidence needed to establish effectiveness.

Jan 2019

Quality Tolerance Limits versus Key Risk Indicators, The Difference

By |2020-02-05T07:40:21+02:00January 18, 2019|Blog, Free Infographics|1 Comment

To clear up confusion surrounding the interpretation and use of QTLs and KRIs, we have created an easy to understand infographic for all clinical research experts involved in quality control.

Nov 2018

Are Clinical Trials Safe? 6 Questions to Ask Before Enrolling

By |2018-11-27T16:53:22+02:00November 27, 2018|Blog|Comments Off on Are Clinical Trials Safe? 6 Questions to Ask Before Enrolling

If you are thinking about joining a clinical research study, then you might wonder about the safety risks you should be aware of, as no clinical trial is completely safe for everyone.

Nov 2018

Patient Profiles – Better Understand Your Patients

By |2020-09-30T13:30:42+02:00November 1, 2018|Blog, Neat Features, RBQM Product Updates|Comments Off on Patient Profiles – Better Understand Your Patients

Pharma today embraces the concept of patient-centered research. Innovators view Patients as informed collaborators whose participation is core to the overall success of clinical research. The risk-based Patient Profiles tool is a key contributor to the modern concept of patient-centered thinking, as It enables early detection and real time control of patient safety issues.

Oct 2018

Data Integration – A Valid Concern or a Convenient Excuse?

By |2020-09-23T10:10:46+02:00October 11, 2018|Blog|Comments Off on Data Integration – A Valid Concern or a Convenient Excuse?

Conference season has started! Our first stop was the Global RBM Summit 2018 in London. Our CSO Dr Johann Proeve was invited to join the conversation as a speaker on the topic “Pragmatic Centralized Monitoring – How to get there?”. Johann shares his observations with us.

Sep 2018

Optimizing Adverse Event Capturing and Reporting – 7 Questions to Ask

By |2018-09-20T06:40:12+02:00September 18, 2018|Blog|Comments Off on Optimizing Adverse Event Capturing and Reporting – 7 Questions to Ask

Adverse Event (AE) reporting, identified by the FDA as one of the most important challenges in clinical research, is known to be prone to under and over-reporting. When starting a project and considering the various ways available to capture the adverse event data, it’s important to ask yourself some analytical questions that help you improve AE and SAE capturing and reporting.

Go to Top